Allogene Therapeutics, Inc.
ALLONasdaqCIK 1737287HealthcareFiscal year ends Dec 31
Reports and events: 137 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-3016:18 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001999371-26-021654 |
| 2026-09-0208:35 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-379423 |
| 2026-08-1216:17 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-056213 |
| 2026-08-1216:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056198 |
| 2026-06-2216:05 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events | 0001628280-26-044618 |
| 2026-05-2817:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-245484 |
| 2026-05-1316:05 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-034585 |
| 2026-05-1316:03 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-034583 |
| 2026-04-3016:37 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001628280-26-028948 |
| 2026-04-1516:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-157140 |
| 2026-04-1316:09 ET | 8-K | 8.01 Other events | 0001193125-26-152866 |
| 2026-04-1307:45 ET | 8-K | 8.01 Other events | 0001193125-26-151999 |
| 2026-03-1216:11 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-017242 |
| 2026-03-1216:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-017230 |
| 2025-11-0616:30 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-050230 |
| 2025-11-0616:28 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-050227 |
| 2025-10-1417:31 ET | 8-K | 8.01 Other events | 0001628280-25-044828 |
| 2025-08-1316:14 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001737287-25-000088 |
| 2025-08-1316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-25-000087 |
| 2025-08-0109:24 ET | 8-K | 8.01 Other events | 0001193125-25-171091 |
| 2025-06-2316:28 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001737287-25-000070 |
| 2025-05-1316:07 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001737287-25-000064 |
| 2025-05-1316:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-25-000063 |
| 2025-04-3018:11 ET | DEF 14A | Proxy statementPeriod 2025-06-18 | 0001737287-25-000049 |
| 2025-03-1316:04 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001737287-25-000036 |
| 2025-03-1316:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-25-000035 |
| 2025-02-2516:18 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-25-035162 |
| 2025-01-2908:35 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-014985 |
| 2024-11-1316:29 ET | 8-K | 8.01 Other events | 0001737287-24-000075 |
| 2024-11-0716:13 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001737287-24-000073 |
| 2024-11-0716:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-24-000072 |
| 2024-10-0716:28 ET | 8-K | 5.05 Item not in the standard list; 9.01 Financial statements and exhibits | 0001737287-24-000062 |
| 2024-08-0716:06 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001737287-24-000056 |
| 2024-08-0716:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-24-000055 |
| 2024-06-1016:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001737287-24-000050 |
| 2024-05-3116:31 ET | 8-K | 1.01 Entry into a material agreement | 0001737287-24-000046 |
| 2024-05-1416:40 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-138316 |
| 2024-05-1316:03 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001737287-24-000041 |
| 2024-05-1316:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-24-000040 |
| 2024-04-2316:31 ET | DEF 14A | Proxy statementPeriod 2024-06-05 | 0001737287-24-000032 |
| 2024-03-1416:55 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001737287-24-000021 |
| 2024-03-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-24-000019 |
| 2024-03-1416:00 ET | 10-K/A | Annual report, amendedPeriod 2022-12-31 | 0001737287-24-000018 |
| 2024-02-1608:30 ET | 8-K | 4.02 Non-reliance on financial statements | 0001193125-24-038107 |
| 2024-01-3118:43 ET | 8-K | 1.01 Entry into a material agreement | 0001737287-24-000003 |
| 2024-01-0508:00 ET | 8-K | 1.01 Entry into a material agreement; 2.05 Exit or disposal costs; 8.01 Other events | 0001193125-24-002888 |
| 2023-12-1915:46 ET | 8-K | 8.01 Other events | 0001737287-23-000096 |
| 2023-11-0216:06 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001737287-23-000091 |
| 2023-11-0216:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001737287-23-000089 |
| 2023-10-1716:34 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001737287-23-000083 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:28 ET. Listed shows no prices and gives no investment advice.